KRAS and familial pancreatic carcinoma: Functional studies conducted in GP2-expressing pancreatic cancer cell lines demonstrated that rs78193826 may impact the activity of KRAS, a key driver of pancreatic cancer (with mutation frequencies >93%) [115].